Skip to main content
GOSS
NASDAQ Life Sciences

Gossamer Bio Q3 Loss Narrows to $48M; Cash Runs Only Into Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$10.15
Mkt Cap
$68.927M
52W Low
$8.29
52W High
$309.6
52W Position info
22% above low
Off High info
97% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

GOSS sits 22% above its 52-week low of $8.29 on light trading volume (0.4× avg).

Summary

Gossamer Bio posted a $48.1 million Q3 loss and ended September with $51.2 million in cash, enough to fund operations only into Q1 2027. The $125 million second closing of its private placement hinges on FDA accepting the seralutinib NDA for filing in 2026.


Key Events · Earnings and Guidance · GOSS

  • Q3 Loss of $48.1 Million

    Net loss was $48.1 million for the three months ended September 30, 2026, versus $48.2 million a year earlier; nine-month loss narrowed to $77.8 million from $123.1 million.

  • Cash Only Funds Operations Into Q1 2027

    Cash and cash equivalents were $51.2 million at September 30, 2026, and management states existing cash is not sufficient to fund operating plans for at least one year, raising substantial doubt about going concern.

  • Revenue Inflated by Chiesi Termination

    Q3 revenue of $38.4 million included $37.1 million of contract liabilities released as revenue when the Chiesi collaboration terminated on July 23, 2026; no further revenue is expected under that agreement.

  • $125 Million Second Closing Hinges on FDA

    The August 2026 private placement's second closing for roughly $125 million requires FDA acceptance of the seralutinib NDA for filing in 2026; if it does not occur by December 31, 2026, that tranche and the FDA Approval Warrants terminate.


Analysis · GOSS · Life Sciences

The headline $48.1 million quarterly loss flatters the underlying operations: $37.1 million of Chiesi deferred revenue was pulled forward as revenue when the collaboration was terminated on July 23, 2026, and the $43.8 million debt-extinguishment gain from the June exchange sits in the nine-month numbers. Strip those out and the company is still burning cash, with $51.2 million on hand and management saying that only funds operations into the first quarter of 2027. The $84.5 million warrant liability is a non-cash mark-to-market on the August private placement warrants, not new dilution or a cash obligation. The real swing factor is the $125 million second closing of that placement, which is contingent on the FDA accepting the seralutinib NDA for filing in 2026; if it does not happen by December 31, 2026, that tranche and the FDA Approval Warrants terminate.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $10.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $8.29 to $309.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $10.15 info
Change: -$1.04 (-9%) info
Market Cap: $68.927M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $10.15 info
Change: -$0.850 (-8%) info
Market Cap: $68.927M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $10.15 info
Change: -$0.780 (-7%) info
Market Cap: $68.927M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $10.15 info
Change: Reverse Stock Split info
Market Cap: $68.927M info
GOSS
Sep 11, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $10.15 info
Change: Reverse Stock Split info
Market Cap: $68.927M info